argenx SE（ARGX）资讯与事件ARGXargenx SE

Argenx Announces New Data from Phase 3 Study of Vyvgart Hytrulo

Argenx announced that new data from the Phase 3 study evaluating Vyvgart Hytrulo in patients with autoimmune myositis, focused on immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM, will be featured as a late-breaking oral presentation during the American College of Rheumatology, or ACR, Convergence 2026 from November 6-11, 2026, in Orlando, Florida. The Phase 3 ALKIVIA study met its primary endpoint, achieving a 15.4-point greater improvement in mean Total Improvement Score, or TIS, versus placebo at Week 52 in the combined IMNM and DM population. Improvements in disease activity for the combined IMNM and DM population were observed as early as Week 4 and were sustained through the full 52 weeks of treatment, even with steroid tapering. A greater proportion of IMNM as well as DM patients achieved a mean total improvement score of 40 or more when treated with efgartigimod versus placebo. The median time to reach TIS greater than or equal to 40 was also shorter with efgartigimod for both subtypes and was sustained through the full 52 weeks of treatment. Efgartigimod was well-tolerated in the study. The observed safety profile of efgartigimod was consistent with prior studies and the known safety profile of efgartigimod.

Argenx Shares Drop 14.4% to $795.00

Argenx is down -14.4%, or -$133.44 to $795.00.

Immunovant Shares Down 6% to $30.05

Shares of Immunovant (IMVT), which has an ongoing Phase 2b Sjogren's disease study, are down 6% to $30.05 in morning trading.